Search Results
Your search for ,foR matches 32687 pages
Showing 29251 - 29300FDA Approves Cobimetinib in Combination With Vemurafenib for Metastatic Melanoma
On November 10, 2015, the U.S. Food and Drug Administration (FDA) approved the MEK inhibitor cobimetinib (Cotellic) in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat metastatic or unresectable melanoma in patients whose tumors express the BRAF V600E or V600K mutation. Approval...
A Selfless Act
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Cancer Cured My Life
The following essay by Richard M. Levine, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which is coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and the bigcasino.org. I’m a...
Engaging Clinicians in the Collection of Cancer Registry Data to Improve Clinical Research
In June, the Commission on Cancer of the American College of Surgeons published a revision of its Facility Oncology Registry Data Standards (FORDS) manual, which contains all the data items, codes, and rules to abstract data into cancer registries at the more than 1,500 Commission on...
Clinical Trials Actively Recruiting Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. The trials are investigating combination treatments; modified chemotherapy regimens; autologous hematopoietic cell...
The Importance of Supporting the Role of Women Leaders in Oncology
I am honored to be the 52nd President of ASCO and thrilled to have followed in the steps of six remarkable women to hold this important leadership position in a professional Society that represents nearly 40,000 oncologists around the world caring for people with cancer. My six female predecessors...
Pilot Study: Research Team Used Focused Ultrasound to Open Blood-Brain Barrier in Patient With Malignant Brain Tumor
A team at Sunnybrook Health Sciences Centre in Toronto has used focused ultrasound to enable temporary and targeted opening of the blood-brain barrier, allowing the more effective delivery of chemotherapy into a patient’s malignant brain tumor. This is the first known report of the noninvasive...
ASCO Launches TAPUR to Assess the Off-Label Use of Targeted Therapies for Patients With Advanced Cancers
Two years ago, Richard L. Schilsky, MD, FACP, FASCO, Chief Medical Officer of ASCO, proposed a unique clinical trial concept during an educational session on the challenges of delivering precision medicine services in a community setting at ASCO’s Annual Meeting. The idea was to design a clinical...
Trabectedin in Unresectable or Metastatic Liposarcoma or Leiomyosarcoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 23, 2015, trabectedin (Yondelis) was approved for the...
The Role of Botulinum Toxin in Head and Neck Cancer
Head and neck cancer and its treatment can result in a variety of neuromuscular and musculoskeletal pain and functional sequelae. Commonly seen conditions in patients with the disease include neck pain and spasm, hemifacial spasm, trismus, dysphonia, dysarthria, neuropathic pain, and salivary...
Diet and Cancer: How Will We Make Progress?
Not only is breast cancer among the most common cancers in women, but it is also one of the most common causes of premature death. Rates of death from the disease vary widely around the world, reflecting variations in risk, screening, and access to highest quality treatment. Although female gender...
Mediterranean Diet Supplemented With Extra-Virgin Olive Oil Reduces Risk for Invasive Breast Cancer
As reported in JAMA Internal Medicine by Estefania Toledo, MD, MPH, PhD, and colleagues, a large Spanish primary prevention nutrition intervention trial in patients at high cardiovascular risk (PREDIMED) showed a large reduction in the risk for invasive breast cancer among women 60 to 80 years of...
American Board of Internal Medicine Names Richard G. Battaglia, MD, FACP, Chief Medical Officer
The American Board of Internal Medicine (ABIM) announced that Richard G. Battaglia, MD, FACP, has joined the senior leadership team of the organization and will serve as Chief Medical Officer, leading ABIM’s effort to incorporate feedback from practicing physicians and key stakeholders into...
The X-Ray Era: 1901–1915
A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The X-ray Era: 1901–1915.” To view additional...
Checkmate 057: Nivolumab Improves Survival vs Docetaxel in Advanced Nonsquamous Non–Small Cell Lung Cancer
In the phase III CheckMate 057 trial, reported in The New England Journal of Medicine by Hossein Borghaei, DO, of Fox Chase Cancer Center, and colleagues, the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) improved overall survival vs docetaxel in patients with advanced...
Graviola
The use of dietary supplements by patients with cancer has increased significantly over the past 25 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the ...
A Shrink Tells the Inside Story of Psychiatry
Bookmark Title: Shrinks: The Untold Story of PsychiatryAuthor: Jeffrey A. Lieberman, MD, with Ogi OgasPublisher: Little, Brown and CompanyPublication date: March 10, 2015Price: $28.00, hardcover; 352 pages Jeffrey A. Lieberman, MD, is the Lawrence C. Kolb Professor and Chairman of Psychiatry at...
Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma: Findings With Nivolumab and Cabozantinib
In the October 25 issue of The ASCO Post, we presented two important studies in previously treated advanced renal cell carcinoma, including the paper by Motzer et al “Nivolumab versus everolimus in advanced renal-cell carcinoma” (CheckMate 025), published in The New England Journal of Medicine,...
Updated Guidelines for Treating Stage IV NSCLC: Trying to Keep Up
In late August 2015, Gregory A. Masters, MD, and colleagues published an update to the ASCO guidelines for systemic therapy for stage IV non–small cell lung cancer (NSCLC), summarized in this issue of The ASCO Post.1 This builds on the full guidelines published in 20092 and the additional switch...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC
As reported in the Journal of Clinical Oncology by Gregory A. Masters, MD, and colleagues, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC).1 Recommendations are based on an update committee systematic review of randomized...
ACS Breast Cancer Screening Guidelines: Balancing the Benefits and Harms of Mammography
For the past 30 years, mammography screening has been one of the most contentious issues in medicine. Controversy has generally centered on the age at which to begin mammography screening (40 vs 50 years) and also, to a lesser extent, on the age at which it should stop. The recent American Cancer...
Getting the Content and the Message Right in Breast Cancer Screening Guidelines
According to recent national headlines, the American Cancer Society (ACS) now recommends that women at average risk of breast cancer should “screen later and less often.”1 While the new ACS recommendations (summarized in this issue of The ASCO Post) might initially be taken as casting doubt on the...
ACS Guideline Update on Breast Cancer Screening for Women at Average Risk
As reported in JAMA by Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, the American Cancer Society (ACS) has issued an update to its 2003 guideline on breast cancer screening for women at average risk of breast cancer.1 Robert A. Smith, PhD, of the...
How QOPI® Is Improving Oncology Care
Launched in 2002 as a pilot program to promote excellence in oncology care, the origins of ASCO’s Quality Oncology Practice Initiative (QOPI®) date as far back as 1997, when the Institute of Medicine (IOM) created a National Cancer Policy Board to assess the state of cancer care in the United...
Support the Conquer Cancer Foundation on Giving Tuesday
Giving Tuesday” is the perfect time to start your holiday giving and take part in a global movement to give back. Giving Tuesday has raised tens of millions of dollars for charities around the world since its start in 2012. Donating to the Conquer Cancer Foundation (CCF) this Giving...
New ASCO Answers Guide to Caregiving
This new ASCO Answers guide helps family caregivers better understand their role in the cancer care team. While there is no one way to be a caregiver, ASCO Answers: Caregiving is designed to help caregivers provide ongoing support as the person with cancer’s needs change. In addition to providing...
Former Conquer Cancer Foundation Grant Recipients Present Research Advances and Share Impact of CCF Grants
Of the $150 million being raised through The Campaign to Conquer Cancer, a planned $56 million will support vital research grants such as the Young Investigator Award (YIA) and Career Development Award (CDA). Over the past 30-plus years, the Conquer Cancer Foundation (CCF) has supported and...
ASCO University® Offers Resources for Palliative and Team-Based Care
ASCO University®, ASCO’s eLearning center, offers an array of courses and programs relevant to palliative care and multidisciplinary team–based cancer care. Below are descriptions of just a few of these offerings. Pain Management Released in March 2015, ASCO University’s “Pain Management Program”...
Applications Open for ASCO’s New Policy Fellowship Program
On October 15, ASCO launched a new fellowship program aimed at providing physicians with the necessary skills to shape cancer policy. ASCO is actively recruiting oncologists in the early phase of their careers that have leadership, civic, policy, or advocacy experience, and a keen interest in...
TAPUR: ASCO’s First Clinical Trial Addresses Critical Gaps in Understanding of and Access to Targeted Therapies
ASCO is preparing to expand the boundaries of precision medicine with the launch of its first clinical trial. At a press briefing during the 2015 ASCO Annual Meeting, the Society formally announced its plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study. At a time when...
The Bridge Project Receives $20 Million Gift From the Commonwealth Foundation for Cancer Research
The Commonwealth Foundation for Cancer Research has pledged $20 million to the Bridge Project, a collaborative research program of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) and Dana-Farber/Harvard Cancer Center (DF/HCC), to accelerate the...
City of Hope Announces New Appointments
City of Hope in Duarte, California, recently announced the following new appointments. Susanne G. Warner, MD Dr. Warner has been appointed Assistant Clinical Professor in the Department of Surgery. She received her medical degree from Texas A&M Health Science Center College of Medicine, where...
Accelerated Partial-Breast vs Whole-Breast Irradiation After Surgery for Early Breast Cancer
As reported in The Lancet by Vratislav Strnad, MD, of University Hospital Erlangen, Germany, and colleagues, 5-year results of a phase III noninferiority trial showed no difference in local relapse, disease-free survival, or overall survival with adjuvant accelerated partial breast irradiation...
Talimogene Laherparepvec for Treatment of Unresectable Cutaneous, Subcutaneous, and Nodal Melanoma Lesions
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 27, 2015, talimogene laherparepvec (Imlygic) was...
Ipilimumab in Adjuvant Treatment of Cutaneous Melanoma With Nodal Involvement
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 28, 2015, ipilimumab (Yervoy) was approved for adjuvant ...
ASH Honors Nancy Speck, PhD, and Karl Welte, MD, With 2015 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize Nancy Speck, PhD, of the University of Pennsylvania Perelman School of Medicine, and Karl Welte, MD, of Hannover Medical School, with the 2015 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
Alfred Goldberg, PhD, and Paul Richardson, MD, to Present 2015 ASH Ernest Beutler Lecture
The American Society of Hematology (ASH) will honor Alfred Goldberg, PhD, of Harvard Medical School, and Paul Richardson, MD, of Dana-Farber Cancer Institute, with the 2015 Ernest Beutler Lecture and Prize for their significant research advances in the area of proteasome inhibitors and their...
The State of Progress in Hematologic Malignancies
The number of targeted therapies approved by the U.S. Food and Drug Administration (FDA) in the treatment of a variety of cancers, especially hematologic malignancies, continues to rise. In 2014 alone, 4 of the 10 new agents directed at discrete molecular targets approved by the FDA were for blood...
Oncologists Encouraged to Learn More About Lesser-Known Heritable Gastrointestinal Cancers
The genetic basis for inherited colorectal cancer is proving to be a much bigger and more complicated “pie” than was appreciated just a few years ago, according to Michael Hall, MD, Director of Gastrointestinal Risk Assessment at Fox Chase Cancer Center, Philadelphia. “With next-generation...
Centers for Medicare & Medicaid Services Releases 2016 Medicare Physician Fee Schedule: Impact on Radiation Oncology
The final 2016 Medicare Physician Fee Schedule released October 30, 2015, by the Centers for Medicare & Medicaid Services (CMS) included cuts to radiation oncology clinics that were slightly less severe than anticipated, according to a news release issued by the American Society for Radiation...
ASH Announces Stephen S. Chung, MD, as Inaugural Jake Wetchler Foundation ASH Scholar for Pediatric Innovation Recipient
The American Society of Hematology (ASH) recently announced that Stephen S. Chung, MD, will receive the inaugural Jake Wetchler Foundation ASH Scholar Award for Pediatric Innovation for his research on the mechanisms of bone marrow failure syndromes. This work could ultimately lead to an improved...
Expert Point of View: Peter Naredi, MD, and Michael Brada, MD
Peter Naredi, MD, European CanCer Organization (ECCO) Scientific Co-Chair of the Congress, stated in a press release: “In my view, Dr. Brastianos and colleagues very elegantly show what we mean with precision medicine, how genetic profiling can support our understanding of the metastatic process,...
Actionable Targets Identified in Brain Metastases
New research shows that paired primary tumor and brain metastases share a common ancestor, but as the metastases develop in the brain, they exhibit novel genetic alterations that can activate a number of signaling pathways. More than half of the mutations represent potential therapeutic targets....
Expert Point of View: Vincent Grégoire, MD, PhD
I am actually not comfortable discussing this analysis,” said formal discussant Vincent Grégoire, MD, PhD, of the Department of Radiation Oncology, St-Luc University Hospital, Brussels, Belgium. “Instead of me you need a biostatistician. Nevertheless, I will try to address the study.” “The study...
Lenvatinib in Refractory Thyroid Cancer: Survival Benefit or Not?
In the original phase III SELECT trial, no overall survival benefit was observed for lenvatinib (Lenvima) vs placebo in progressive radioactive iodine–refractory differentiated thyroid cancer. Overall survival was a secondary endpoint in that trial. However, in an updated analysis of SELECT, which...
More Data From ECC 2015
Updated analysis of the STAMPEDE trial found no benefit for zoledronic acid in reducing deaths or skeletal-related events and confirmed the overall survival benefit of docetaxel in men with advanced hormone-sensitive prostate cancer. MDV3100, in advanced triple-negative breast cancer, found a...
Quick Takes From ECC 2015 Include New Data in Melanoma, Prostate and Breast Cancers, and Renal Cell Carcinoma
The 2015 European Cancer Congress (ECC), held recently in Vienna, represented the combined efforts of the European Cancer Organisation (ECCO), the European Society for Medical Oncology (ESMO), and other partner organisations, constituting the largest European platform for oncology education. At...
Expert Point of View: Paul M. Busse, MD, PhD
HPV-associated oropharyngeal cancer is becoming more and more prevalent. This is a ‘different beast’—distinct from the squamous cell carcinomas of the tonsil and tongue that arise from standard risk factors of tobacco and alcohol. Patients without a smoking history have an 85% to 90% cure rate,...
Evidence Mounts for Less-Intense Chemoradiation Therapy for Low-Risk Oropharyngeal Cancer
A new study shows that deintensification of chemoradiation therapy translates to excellent pathologic complete response rates in low-risk human papillomavirus (HPV)-associated oropharyngeal cancer.1 Patient-reported outcomes showed that side effects declined after 8 weeks. The hope is that these...
Howard Hochster, MD, Named President-Elect of ISGIO
The International Society of Gastrointestinal Oncology (ISGIO) has named Howard Hochster, MD, as President-Elect. Dr. Hochster, Professor of Medical Oncology; Associate Director for Clinical Sciences at Yale Cancer Center; and Director of the Gastrointestinal Cancers Program at Smilow Cancer...
